Carrageenan is widely used in the pharmaceutical, textile and cosmetic industries as a filler, emulsifier, thickener, and gelling agent. Carrageenan fiber is well recognized for slowing down the absorption of fat and glucose from the solution of the gastrointestinal tract into the bloodstream, which is good for decreasing blood glucose levels. In this study, male white Wilstar breed rats with pancreatic injury from alloxan induction were used as test subjects to assess the in vivo hypoglycemic effect of iota carrageenan from Eucheuma spinosum. Five test groups were divided for this treatment. Group I (negative control) was given alloxan induction without therapy, group II (positive control) was treated with metformin; group III was given carrageenan suspension at a dose of 25 mg/KgBW, group IV was given carrageenan suspension at a dose of 50 mg/KgBW, group V Carrageenan suspension was given at a dose of 75 mg/KgBW. The Normality, Homogeneity, and Kruskal-Wallis tests were used in statistical analysis, followed by the Mann-Whitney test. According to the finding, iota carrageenan had an effect on reducing blood sugar levels in alloxan-induced rats. The most influential group showing anti-diabetic effect was treatment group III (75 mg/kgBW) of 35.38% when compared to treatment group II (50 mg/kgBW) of 32.80% and treatment group I (25 mg/kgBW) of 21.31%.